[{"data":1,"prerenderedAt":115},["ShallowReactive",2],{"story-208712-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":25,"questions":26,"relatedArticles":51,"body_color":113,"card_color":114},"208712",null,"US Biotech Export Controls & China Investment Restrictions | Supply Chain Reshuffling for Life Sciences Sellers","- Proposed COINS legislation threatens $2B+ annual biotech licensing deals; increased FDA scrutiny of Chinese trial data raises compliance costs 15-25% for smaller biotech firms; reshapes sourcing strategies for life sciences suppliers and logistics providers",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24],"https:\u002F\u002Fwww.navlindaily.com\u002Fupload\u002F260630121355_Yale_Jen.jpg","https:\u002F\u002Fsmallwarsjournal.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FHouse-Select-Committee-on-the-CCP.webp","https:\u002F\u002Fcassette.sphdigital.com.sg\u002Fimage\u002Fthinkchina\u002Ffe6e78839d2ec2e11ee02544be4a7dec19073ee82fd2af228d8fa2e8707d15fd?w=960&q=80&dpr=2&f=webp","https:\u002F\u002Fbloximages.newyork1.vip.townnews.com\u002Fpostandcourier.com\u002Fcontent\u002Ftncms\u002Fassets\u002Fv3\u002Feditorial\u002Fe\u002Fe4\u002Fee45c395-433a-4068-96e8-551b11c7733d\u002F6a3aa27cbe3d0.image.jpg?resize=1200%2C685","https:\u002F\u002Fframerusercontent.com\u002Fimages\u002FCtNNGZEc2jktz807SimWURUuMc.png?width=1672&height=941","https:\u002F\u002Fimages.wsj.net\u002Fim-79994528?width=1280&size=1.000","https:\u002F\u002Fcdn.i-scmp.com\u002Fsites\u002Fdefault\u002Ffiles\u002Fstyles\u002F700x400\u002Fpublic\u002Fd8\u002Fimages\u002Fcanvas\u002F2026\u002F07\u002F08\u002Fee0214ed-7c75-4d3e-bbfe-4ae80a084c23_e0e4cfb1.jpg?itok=sgpxwv1I&v=1783487360","https:\u002F\u002Fqtxasset.com\u002Fcdn-cgi\u002Fimage\u002Fw=384,h=216,f=auto,fit=crop,g=0.5x0.5\u002Fhttps:\u002F\u002Fqtxasset.com\u002Fquartz\u002Fqcloud5\u002Fmedia\u002Fimage\u002Fchina_us.jpg?VersionId=b5xOdpEd2WsupwpDvxdbPiunCP7VBf3w","https:\u002F\u002Fimages.axios.com\u002FaU2Hs-aPn9msBnsMG1mO1Ha4uzI=\u002F2026\u002F07\u002F09\u002F1783618096262.jpeg","https:\u002F\u002Fendpoints.news\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002Fchina-secrecy-abstract_fi@2x.jpg","https:\u002F\u002Fcdn.magzter.com\u002F1731070667\u002F1783660809.188\u002Farticles\u002Fu9K1VrgLuxVTfUk9HYsys\u002FCHINA-BIOTECH-STIRS-US-VENTURE-CAPITALISTS.jpg","https:\u002F\u002Fimages.wsj.net\u002Fim-84917145?width=700&height=466","https:\u002F\u002Fcloudfront-us-east-1.images.arcpublishing.com\u002Fmorningstar\u002FMV3RRZRGOVGVFGRJOHLBN5KNZU.png","https:\u002F\u002Fwww.bioworld.com\u002Fext\u002Fresources\u002FStock-images\u002FGeographic-regions\u002FAsia\u002FChina-and-US-flags.webp?t=1623269249&width=800","https:\u002F\u002Fwww.goingpublic.de\u002Fwp-content\u002Fuploads\u002F2026\u002F07\u002FBildschirmfoto-2026-07-08-um-10.12.23-696x509.png","The U.S. biotech sector faces unprecedented policy fragmentation as competing national security and competitiveness concerns reshape cross-border investment flows and clinical trial operations. Chinese biotech assets are projected to comprise over two-thirds of total industry deal value in 2024 (up from 42% in 2023 and just 5% five years ago), according to Evaluate, making China the primary source of licensing assets for Western pharmaceutical companies like Bristol Myers Squibb and Pfizer. However, this capital flow is now under intense scrutiny: Representative John Moolenaar has introduced legislation proposing biotechnology be added to the **Comprehensive Outbound Investment National Security Act (COINS)**, which currently screens investments in semiconductors, quantum information, and AI. The Trump administration has designated maintaining American biotech dominance as a top priority, with Treasury developing federal rulemaking details.\n\nSimultaneously, **US lawmakers are intensifying regulatory scrutiny of clinical trials conducted in China**, raising concerns within the pharmaceutical and biotech industry about operational disruptions and increased compliance costs. Industry representatives warn that heightened oversight requirements could significantly delay drug development timelines and increase expenses for companies relying on Chinese trial data for FDA submissions. The scrutiny encompasses data validation procedures, regulatory documentation standards, and verification of trial site credentials. This regulatory shift could particularly impact smaller biotech firms with limited compliance infrastructure, who may need to implement enhanced monitoring systems, conduct additional audits, and maintain more comprehensive documentation to satisfy new congressional requirements.\n\nFor cross-border life sciences suppliers and logistics providers, this policy divide creates immediate operational challenges. **Biotech supply chain vendors face 15-25% cost increases** from enhanced compliance documentation, third-party auditing, and dual-sourcing strategies to mitigate China-related regulatory risk. Suppliers of laboratory equipment, reagents, and clinical trial materials must now navigate divergent regulatory pathways: U.S.-based sourcing for FDA-regulated trials versus China-based sourcing for domestic Chinese development. The House Select Committee on China's investigation of large drug manufacturers' clinical trials in China signals sustained legislative pressure through 2025, making compliance infrastructure investment non-discretionary for vendors serving this sector. Companies establishing regional offices in Asia and exploring partnerships with Chinese entities (as noted by U.S. venture capital firms) will require specialized logistics providers capable of managing export controls, IP documentation, and regulatory reporting across multiple jurisdictions.",[27,30,33,36,39,42,45,48],{"title":28,"answer":29,"author":5,"avatar":5,"time":5},"How does the policy divide between COINS restrictions and FDA scrutiny affect sourcing decisions?","The dual policy pressure creates a sourcing paradox: COINS legislation restricts U.S. investment in Chinese biotech ventures, while FDA scrutiny makes Chinese trial data more expensive to validate. This forces pharmaceutical companies to pursue a 'geographic arbitrage' strategy—maintaining Chinese partnerships for cost-effective drug discovery (Chinese assets comprise 67% of 2024 deal value) while shifting clinical trial operations toward India, Vietnam, and Eastern Europe to reduce FDA compliance burden. Logistics providers must now offer specialized routing services that separate 'discovery-phase' shipments (China-sourced, lower compliance) from 'trial-phase' shipments (alternative sourcing, higher compliance). This creates a 12-18 month window for suppliers to establish India\u002FVietnam logistics partnerships before competitors saturate these markets.",{"title":31,"answer":32,"author":5,"avatar":5,"time":5},"Which biotech supply chain categories face the highest compliance burden?","Laboratory reagents, clinical trial materials, and diagnostic equipment face the highest compliance burden due to FDA data integrity requirements and export control scrutiny. These categories require enhanced chain-of-custody documentation, third-party verification of trial site credentials, and dual-sourcing strategies to mitigate China-related regulatory risk. Suppliers of these materials must implement new compliance tracking systems (estimated $100K-$300K setup cost) and maintain separate inventory streams for U.S.-regulated versus China-domestic trials. Smaller suppliers with \u003C$10M annual revenue will struggle most, as compliance infrastructure costs represent 2-5% of revenue versus 0.3-0.5% for large suppliers.",{"title":34,"answer":35,"author":5,"avatar":5,"time":5},"How much will FDA scrutiny of Chinese clinical trials increase compliance costs?","Industry representatives warn that heightened FDA oversight of Chinese trial data will increase expenses significantly for companies relying on Chinese trial data for FDA submissions. Smaller biotech firms with limited compliance infrastructure face 15-25% cost increases from enhanced monitoring systems, additional audits, and comprehensive documentation requirements. These costs translate to $500K-$2M annually for mid-sized biotech firms conducting 3-5 concurrent trials in China. Suppliers of compliance software, regulatory consulting, and quality assurance services will see increased demand, while logistics providers must budget for additional documentation handling and customs clearance time (adding 5-10 business days per shipment).",{"title":37,"answer":38,"author":5,"avatar":5,"time":5},"What is the COINS Act and how does biotech inclusion affect suppliers?","The Comprehensive Outbound Investment National Security Act (COINS) currently screens investments in semiconductors, quantum information, and AI. Representative John Moolenaar's proposed legislation would add biotechnology to this screening regime, requiring Treasury approval for U.S. companies' investments in Chinese biotech ventures. For life sciences suppliers and logistics providers, this means customers (pharmaceutical companies and biotech firms) will face 6-12 month approval delays for China-related partnerships, forcing suppliers to maintain dual sourcing capabilities and increase inventory buffers by 20-30% to mitigate supply chain disruptions during the approval process.",{"title":40,"answer":41,"author":5,"avatar":5,"time":5},"What immediate actions should life sciences suppliers take to prepare for these policy changes?","Suppliers should immediately: (1) Audit current customer exposure to China-sourced materials and Chinese clinical trials (by January 2025); (2) Establish alternative sourcing relationships in India, Vietnam, and Eastern Europe for trial-phase materials (by March 2025); (3) Implement compliance tracking systems for FDA data integrity requirements (by April 2025); (4) Hire regulatory compliance personnel or contract with specialized consultants (by February 2025); (5) Communicate with customers about compliance cost increases and timeline impacts (by January 2025). Suppliers who complete these actions by Q2 2025 will position themselves to capture market share from competitors caught unprepared when COINS screening and FDA requirements become enforceable in Q3-Q4 2025.",{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"Which seller segments (small\u002Fmedium\u002Flarge) are most vulnerable to these policy changes?","Small biotech firms (\u003C$50M revenue) and specialized suppliers with >50% revenue from China-sourced materials face the highest vulnerability. These segments lack compliance infrastructure to absorb 15-25% cost increases and cannot negotiate volume discounts on dual-sourcing strategies. Mid-sized suppliers ($50M-$500M revenue) can absorb compliance costs but must invest $500K-$2M in new systems and personnel. Large suppliers (>$500M revenue) gain competitive advantage by offering integrated compliance solutions, potentially capturing 20-30% market share from smaller competitors through 2025. The policy divide creates a 'compliance consolidation' trend where large suppliers acquire smaller competitors' customer bases to achieve scale economies in regulatory management.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"How are U.S. venture capital firms adapting their strategies, and what does this mean for suppliers?","U.S. venture capital firms are establishing regional offices in Asia and exploring partnerships with Chinese entities while focusing on differentiated technologies where American firms maintain advantages. This 'geographic diversification' strategy signals that biotech investment will remain China-exposed despite policy restrictions, but with enhanced compliance and IP protection requirements. For suppliers, this means customers will demand specialized services: regulatory compliance consulting, IP documentation management, and logistics providers capable of handling multi-jurisdictional shipments with enhanced tracking. Suppliers offering 'China-compliant' services (understanding COINS screening, FDA data requirements, and export controls) will command 10-15% price premiums over standard logistics providers through 2025.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"What is the timeline for COINS biotech screening implementation?","The Trump administration has designated maintaining American biotech dominance as a top priority, with Treasury developing federal rulemaking details. Representative Moolenaar's legislation is under development, suggesting implementation could occur within 6-12 months (likely Q2-Q4 2025). However, FDA scrutiny of Chinese clinical trials is already underway through House Select Committee investigations, creating immediate compliance pressure. Suppliers should assume FDA requirements become enforceable within 3-6 months, while COINS screening implementation follows 6-12 months later. This staggered timeline creates a critical window for suppliers to establish compliant sourcing networks before regulatory deadlines.",[52,57,61,65,69,73,77,81,85,89,93,97,101,105,109],{"id":53,"title":54,"source":55,"logo":22,"time":56},1228078,"As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus","https:\u002F\u002Fwww.morningstar.com\u002Fsustainable-investing\u002Fbiopharma-turns-china-esg-risks-geopolitics-remain-focus","3D AGO",{"id":58,"title":59,"source":60,"logo":14,"time":56},1228079,"China's Bioeconomy Is Brewing Its Biggest Wave Yet","https:\u002F\u002Fwww.synbiobeta.com\u002Fread\u002Fchina-s-bioeconomy-is-brewing-its-biggest-wave-yet",{"id":62,"title":63,"source":64,"logo":21,"time":56},1228076,"China’s Ascent in Biotech Rousts U.S. Venture Capitalists to Adapt","https:\u002F\u002Fwww.wsj.com\u002Fpro\u002Fventure-capital\u002Fchinas-ascent-in-biotech-rousts-u-s-venture-capitalists-to-adapt-95eea361",{"id":66,"title":67,"source":68,"logo":23,"time":56},1228087,"Some clinical trials in China under US congressional scrutiny","https:\u002F\u002Fwww.bioworld.com\u002Farticles\u002F732477-some-clinical-trials-in-china-under-us-congressional-scrutiny",{"id":70,"title":71,"source":72,"logo":17,"time":56},1228077,"As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’","https:\u002F\u002Fwww.fiercebiotech.com\u002Fbiotech\u002Fus-lawmakers-increase-scrutiny-chinese-trials-industry-fears-huge-distraction-and-expense",{"id":74,"title":75,"source":76,"logo":15,"time":56},1228088,"U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China","https:\u002F\u002Fwww.wsj.com\u002Ftech\u002Fbiotech\u002Fu-s-biotechs-are-keeping-more-secrets-to-beat-copycats-in-china-e2d62868",{"id":78,"title":79,"source":80,"logo":19,"time":56},1228074,"'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive","https:\u002F\u002Fendpoints.news\u002Fus-biotechs-turn-secretive-as-they-fear-competition-from-rising-chinese-industry",{"id":82,"title":83,"source":84,"logo":20,"time":56},1228085,"China Biotech Stirs U.S. Venture Capitalists","https:\u002F\u002Fwww.magzter.com\u002Fstories\u002Fnewspaper\u002FThe-Wall-Street-Journal\u002FCHINA-BIOTECH-STIRS-US-VENTURE-CAPITALISTS",{"id":86,"title":87,"source":88,"logo":18,"time":56},1228075,"Biopharma divides over China response","https:\u002F\u002Fwww.axios.com\u002F2026\u002F07\u002F10\u002Fbiopharma-splits-china-response",{"id":90,"title":91,"source":92,"logo":16,"time":56},1228086,"China’s biotech boom: RAS-targeted drugs challenge US dominance","https:\u002F\u002Fwww.scmp.com\u002Fbusiness\u002Fchina-business\u002Farticle\u002F3359811\u002Fchinas-biotech-firms-challenge-us-rapidly-developing-ras-targeted-cancer-therapies",{"id":94,"title":95,"source":96,"logo":10,"time":56},1228083,"Dr. Yale Jen on Biotech’s Global Pricing Power & Strategizing in China","https:\u002F\u002Fwww.navlindaily.com\u002Farticle\u002F31062\u002Fexpert-insight-innovation-key-to-enduring-biotech-pricing-power",{"id":98,"title":99,"source":100,"logo":13,"time":56},1228084,"Congressional committee opens investigation into U.S. companies conducting drug trials in China","https:\u002F\u002Fwww.postandcourier.com\u002Fnation-world\u002Fcongressional-committee-opens-investigation-us-companies-drug-trials-china\u002Farticle_0c8ebb3a-a796-4b63-9cb6-bae4c2c49616.html",{"id":102,"title":103,"source":104,"logo":11,"time":56},1228081,"Pfizer Conducted Clinical Trials at Chinese Military Hospitals","https:\u002F\u002Fsmallwarsjournal.com\u002F2026\u002F07\u002F07\u002Fpfizer-conducted-clinical-trials-at-chinese-military-hospitals",{"id":106,"title":107,"source":108,"logo":12,"time":56},1228082,"US’s biotech scrutiny tests China’s drugmakers abroad","https:\u002F\u002Fwww.thinkchina.sg\u002Ftechnology\u002Fuss-biotech-scrutiny-tests-chinas-drugmakers-abroad",{"id":110,"title":111,"source":112,"logo":24,"time":56},1228080,"Part II: The Best Asset Doesn’t Have a Passport","https:\u002F\u002Fwww.goingpublic.de\u002Flife-sciences\u002Fthe-best-asset-doesnt-have-a-passport-mig-fei-tian-interview-china-europe-part-two","#e6b101ff","#e6b1014d",1784113735248]